These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 25608663)

  • 21. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
    Saborowski A; Vogel A; Segatto O
    Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric transcripts observed in non-canonical FGFR2 fusions with partner genes' breakpoint located in intergenic region in intrahepatic cholangiocarcinoma.
    Yin L; Han Z; Feng M; Wang J; Xie Z; Yu W; Fu X; Shen N; Wang X; Duan A; Zhang Y; Ma J
    Cancer Genet; 2022 Aug; 266-267():39-43. PubMed ID: 35749865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
    Braun S; McSheehy P; Litherland K; McKernan P; Forster-Gross N; Bachmann F; El-Shemerly M; Dimova-Dobreva M; Polyakova I; Häckl M; Zhou P; Lane H; Kellenberger L; Engelhardt M
    Expert Opin Investig Drugs; 2021 Nov; 30(11):1071-1080. PubMed ID: 34698609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
    Moeini A; Sia D; Bardeesy N; Mazzaferro V; Llovet JM
    Clin Cancer Res; 2016 Jan; 22(2):291-300. PubMed ID: 26405193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection.
    Buckarma E; De La Cruz G; Truty M; Nagorney D; Cleary S; Kendrick M; Borad M; Graham RP; Gores G; Smoot R
    HPB (Oxford); 2022 Oct; 24(10):1748-1756. PubMed ID: 35718679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
    Borad MJ; Gores GJ; Roberts LR
    Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
    Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
    Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
    Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyclonal Secondary
    Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
    Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
    Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
    Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
    [No Abstract]   [Full Text] [Related]  

  • 32. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
    Tannapfel A; Sommerer F; Benicke M; Katalinic A; Uhlmann D; Witzigmann H; Hauss J; Wittekind C
    Gut; 2003 May; 52(5):706-12. PubMed ID: 12692057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gatekeeper Mutations and Intratumoral Heterogeneity in
    Smyth EC; Babina IS; Turner NC
    Cancer Discov; 2017 Mar; 7(3):248-249. PubMed ID: 28264865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
    Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
    JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis.
    Niu S; Zhang Y; Li Z; Wang T
    Liver Int; 2024 Sep; 44(9):2208-2219. PubMed ID: 38829010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy.
    Scheiter A; Keil F; Lüke F; Grosse J; Verloh N; Opitz S; Schlosser S; Kandulski A; Pukrop T; Dietmaier W; Evert M; Calvisi DF; Utpatel K
    Curr Oncol; 2021 Mar; 28(2):1161-1169. PubMed ID: 33800328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
    Mazzaferro V; El-Rayes BF; Droz Dit Busset M; Cotsoglou C; Harris WP; Damjanov N; Masi G; Rimassa L; Personeni N; Braiteh F; Zagonel V; Papadopoulos KP; Hall T; Wang Y; Schwartz B; Kazakin J; Bhoori S; de Braud F; Shaib WL
    Br J Cancer; 2019 Jan; 120(2):165-171. PubMed ID: 30420614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific recognition of an
    White BS; Sindiri S; Hill V; Gasmi B; Nah S; Gartner JJ; Prickett TD; Li Y; Gurusamy D; Robbins P; Rosenberg SA; Leko V
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37045473
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
    Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
    Mahipal A; Tella SH; Kommalapati A; Anaya D; Kim R
    Cancer Treat Rev; 2019 Aug; 78():1-7. PubMed ID: 31255945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.